



# ISCOMAT

## Improving Safety and Continuity Of Medicines management At Transitions of care

**Dr Jon Silcock**

*Joint Programme Leader*

*Joint Work Package 2 Leader*





# Background


NIHR major programme  
grant – in 4 work packages  
(WP 1-4)

Improve the management  
of medicines across care  
transitions

WP 1 & 2 in 4 healthcare  
economies  
WP 3 in 3 healthcare  
economies  
WP4 in 42 acute trusts  
nationwide

Patient participants:  
Heart failure  
(Moderate/EF<45%)

## Stages from Intervention development to trial





# Work Package 1

## Design – WP1

### Whole pathway analysis – resilience perspective

Observations  
in 5  
cardiology  
wards

Patient  
interviews at  
three time  
points (20)

Hospital and  
primary care  
staff  
interviews  
(n=45)

Documentary  
analysis –  
national and  
local policies

Parallel  
'mixed'  
analysis

Map the  
patient  
pathway



## WP1 Summary

Areas of good practice but also ineffective processes, poor communication and lack of co-ordination at different levels of care.

Variation in practice for managing discharges at individual and organisational levels.

Safety is inbuilt but there are temporary fixes and safety gaps.

Policy should explore training for staff across the pathway and involving patients in improving the system.




## Work Package 2

- Experience based co–design (EBCD)
- Working in 4 sites (Yorkshire & the Humber)
- Patient and staff groups jointly agreeing priorities and developing solutions
- Activities framed by a ‘trigger film’ summarising the emotional touch points found in WP1
- Normally, EBCD is carried out in 1 site
- We were running the process in parallel across 4 sites and integrating the outputs



## EBCD priorities from WP2



# Work Package 3: Feasibility Study

Complex  
intervention

Cross pathway

Three sites

30 patients

Follow-up –  
interviews, surveys,  
focus groups





# Work Package 3: Feasibility Study

Refine  
intervention

Staff training

Deliver  
intervention

Patients: Health  
resource use and  
QOL surveys at  
follow-up

Staff survey

Staff interviews  
(approx 3-6 in  
each site)

Observations on  
wards

Patient follow-up  
interviews (20 in  
total)



## Work package 4

- Cluster randomised controlled trial
- 21 control and 21 intervention areas
- Main sites are Acute Trusts
- Patients with moderate LVSD
- Training provided about medicine safety at transitions of care
- Intervention delivered by Cardiology Ward staff:
  - Improving communication in the pathway
  - Providing information about medicines
  - Arranging follow up in the community



## WP4: outcome monitoring

- 12-month follow up post-discharge
- All-cause mortality & heart failure readmission
- Prescribing of key medicines
- Patient experience & satisfaction with care
- Quality of life (EQ-5D)
- Resource use (for economic evaluation)
  
- Using patient questionnaires and where possible routine data (e.g. NICOR audit)



## Trial progress to date

- n=42 sites randomised
- 1207/2100 patients registered
- 2040 patients approached about ISCOMAT
- 5359 patients screened for suitability
  
- Intervention is suitable for all patients meeting the inclusion criteria – registered or not
- Recruitment has generally been slower than planned or expected
- Lots of variation between sites



## Lessons learnt (about care)

- Care pathways are complex and not many people have end-to-end understanding
- Specialist nurses are key professionals but may lack capacity in some areas
- For patients, medicines taking and disease management are social processes
- Better information is needed for all those involved
- Heart failure is one example of a complex, common and chronic disease
- The intervention we have developed is intended to have wider applications

## Lessons learnt (about research)

- There are lots of competing pressures in frontline patient care (we did know this!)
- Intervention was feasibility tested, nevertheless, systems and processes vary lots between trusts
- We are assessing ‘fidelity’ to the intervention – different places have different problems
- It’s hard to maintain a clear distinction between recruitment to the trial & intervention delivery
- More flexible intervention components may be needed – but this raises the issue of internal validity (what would we be testing)



Any  
questions?

Thank you for listening!

